Month: April 2021

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial SHANGHAI and SAN FRANCISCO and ST. HELIER, Jersey, April 13, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocure was informed that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed,...

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions. “We feel privileged to have the opportunity to work with OHSU to focus on developing potential therapies for diseases with clear genetic drivers and severe unmet need,” said BridgeBio founder and CEO Neil Kumar, Ph.D. “OHSU was one of the first research institutions we connected with in the early days of BridgeBio, and we look forward to deepening our relationship through close collaboration with their scientists as we strive to help patients together.” This arrangement builds on five years of informal collaborations between...

TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients. “The Lundquist Institute is renowned for its scientific research and drug discoveries, and we look forward to developing a close relationship with their talented scientists in the hope of translating their discoveries into medicines with meaningful benefit for patients,” said BridgeBio CEO and Founder Neil Kumar, Ph.D. Under the established two-year partnership, BridgeBio will work closely with The Lundquist Institute researchers to identify programs that may have the potential to become therapies...

PALO ALTO, Calif. and EDMONTON, Alberta, April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in glycomics into potential treatments for patients with genetic diseases. “We are thrilled to be partnering with GlycoNet, an institution at the forefront of developing carbohydrate-based drugs to address areas of unmet need,” said BridgeBio founder and CEO Neil Kumar, Ph.D. “We understand the clinical benefit research in glycomics could have for certain genetic diseases and by partnering together, we hope to advance potentially life-changing medicines as rapidly as possible.” BridgeBio will work alongside GlycoNet researchers to identify research programs that...

TORONTO, April 13, 2021 (GLOBE NEWSWIRE) — In accordance with regulatory requirements, Dundee Corporation (TSX: DC.A) (“Dundee”) announces its share ownership following the exercise of warrants to purchase 6,500,000 common shares of Maritime Resources Corp. (the “Issuer”) at $0.15 each for aggregate consideration of $975,000. Dundee and its affiliates own or control 79,440,919 common shares and warrants exercisable for the purchase of 1,741,791 common shares of the Issuer. Immediately prior to the exercise of warrants, Dundee and its affiliates owned or controlled 18.63% of the Issuer on an undiluted basis and 20.97% on a partially diluted basis. Following the exercise of warrants, Dundee owns 19.96% of the Issuer on an undiluted basis and 20.31% on a partially diluted basis. Dundee’s ownership or control of securities of the Issuer...

Clinton Township, Michigan , April 13, 2021 (GLOBE NEWSWIRE) — Resgreen Group (RGGI), a leading mobile robot company, today announced the sale of its Wanda SD to the Sheriff’s Office in Palm Beach Florida (PBSO.ORG), for disinfection of its jail. Wanda SD uses either Ultraviolet C (UVC) light or UVC and Ozone to kill 99.9 percent of harmful bacteria and viruses. “The pandemic continues to be a concern, especially in crowded spaces such as jails, courtrooms and government offices,” said Parsh Patel, CEO of RGGI. “By using Wanda SD, the Palm Beach Sheriff’s Office is taking additional steps to keep their employees and inmates safe from dangerous pathogens. We note the ask for expedited delivery and will meet that challenge.” Wanda SD can sanitize up to 200 square feet in around 15 minutes and is ideal for hotels, offices, schools,...

LANCASTER, Pa., April 13, 2021 (GLOBE NEWSWIRE) — Armstrong Flooring, Inc. (NYSE: AFI) (“Armstrong Flooring” or the “Company”), a leader in the design and manufacture of innovative flooring solutions, announced today that the Company will release its first quarter 2021 financial results before the market opens on Thursday, April 22, 2021. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review financial results, discuss recent events and conduct a question-and-answer session. Webcast and Conference Call:The live webcast will be available through the “Investor Relations” section of the Company’s website, www.armstrongflooring.com. Participants are advised to go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software....

København Ø, April 13, 2021 (GLOBE NEWSWIRE) —   I henhold til vedtægterne indkalder Investeringsforeningen ValueInvest Danmark hermed til ordinær generalforsamling den 28. april 2021. Indkaldelsen med dagsorden fremgår af vedhæftede dokument, som også kan downloades fra foreningens hjemmeside www.valueinvest.dk. Bestyrelsen forInvesteringsforeningen ValueInvest Danmark Vedhæftede filerIndkald OGF ValueInvest – 2021.04.28 Clean Vedtægter ValueInvest – 2021.04.28 inkl. tillæg A 2017.03.28 Mark-up UDKAST

Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007) Top-line data from Phase 3 DERBY and OAKS studies expected in Q3 2021WALTHAM, Mass., April 13, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 24-month data from the Phase 1b APL2-103 study of pegcetacoplan, an investigational targeted C3 therapy, in patients with advanced geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and low vision. GA is a leading cause of blindness that affects approximately five million people worldwide1,2 and has no treatment. The Phase 1b study, designed to enroll approximately 12 patients with bilateral...

– AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON – ROCKVILLE, Md., April 13, 2021 (GLOBE NEWSWIRE) — TeamedOn International, Inc., a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced a licensing agreement to advance gene therapy to treat X-linked retinoschisis (XLRS), an inherited disease that causes loss of vision due to degeneration of the retina in males. Under the terms of the agreement, AGTC will provide TeamedOn with the clinical trial material, pre-clinical and clinical data generated for the development of...